About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Body Composition Monitor in Hemodialysis Patients | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNPhase 4NCT01103167

Body Composition Monitor in Hemodialysis Patients

Control of volume status is a pivotal issue in haemodialysis therapy. Objective and practical management for maintaining normovolemia is needed. The investigators hypothesized that intervention of vo...

Lead sponsor: Gachon University Gil Medical Center•1 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Contacts

Sejoong Kim, MD, PhD

CONTACT

82-32-460-8305 [email protected]

Kwon Wook Joo, MD, PhD

CONTACT

82-2-2072-1964 [email protected]

Sponsors

Lead Sponsor

Gachon University Gil Medical Center

Collaborators

Seoul National University Hospital
Seoul National University Bundang Hospital

The investigators will assess BCM in enrolled hemodialysis patients by 4 weeks for 16 weeks During the former 8-week intervention period, The investigators will adjust patients' volume status according to the results of BCM. During the latter 8-week observational period, The investigators will evaluate the changes of patients' hemodynamic parameters and biomarkers.

Age

18 - 80 years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•6-month or more stable hemodialysis patients
•18 years or more
•less than 5% of changes of dry weight for last 3 months

Exclusion Criteria

•pregnancy
•active malignancy
•cardiac pacemaker or defibrillator
•history of extremity amputation
•active infectious disease within 3 months
•admission history for complication related to hemodialysis within 3 months

Related studies

PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on Hemodialysis

NCT06422871 · End Stage Renal Disease, Hemodialysis Access Failure

CAPABLE Transplant

NCT06326905 · Quality of Life, Depression, and more

Effect of a Plant-Focused Diet on Nutritional Status in Malnourished Peritoneal Dialysis Patients

NCT07157397 · End Stage Renal Disease (ESRD), End Stage Kidney Disease (ESRD), and more

RECRUITINGPhase 3

A Phase 3 Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Adults at High Risk of Delayed Graft Function (DGF) Following Kidney Allograft Transplantation

NCT07020832 · Delayed Graft Function, End Stage Renal Disease, and more

CKD Specific Telemonitoring Platform to Minimize Adverse Outcomes in High Risk CKD Patients

NCT05726526 · Chronic Kidney Disease Stage 5, End Stage Renal Disease

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: April 14, 2010Terms

Trial snapshot

StatusUNKNOWN

PhasePHASE4

Enrollment160

Start dateApr 2010

Last updatedApr 14, 2010

Condition

End Stage Renal Disease

Locations shown

Sejoong Kim

Incheon

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: April 14, 2010Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions